胰高血糖素样肽-1 受体激动剂心血管保护机制的研究进展  

Progress in research on cardiovascular protective mechanismof glucagon-like peptide-1 receptor agonists

作　　者：崔鑫 卫晓彤 颜文慧 陈莉娜 CUI Xin;WEI Xiao-tong;YAN Wen-hui;CHEN Li-na(Department of Pharmacology,School of Basic Medical Sciences,Xi’an Jiaotong University Health Science Center,Xi’an 710061,China)

机构地区：[1]西安交通大学医学部基础医学院药理学系,西安710061

出　　处：《中国新药杂志》2022年第14期1367-1371,共5页Chinese Journal of New Drugs

基　　金：国家自然科学基金资助项目(81471031)。

摘　　要：心血管疾病是2型糖尿病的主要并发症和致死原因,严重威胁糖尿病患者的生存。胰高血糖素样肽-1受体激动剂是一种新型降糖药,具有减重、降低糖化血红蛋白、不良反应发生率低等优点,广泛用于2型糖尿病的治疗。研究表明,胰高血糖素样肽-1受体激动剂可以通过抗氧化应激、抑制炎症反应以及改善胰岛素敏感性等机制发挥心血管保护作用。本文从以上方面综述胰高血糖素样肽-1受体激动剂心血管保护机制的研究进展。Cardiovascular disease(CVD)is the primary complication and cause of death of type 2 diabetes,which seriously threatens the survival of diabetic patients.Glucagon-like peptide-1 receptor agonists have been widely and efficiently used in type 2 diabetes with advantages of losing weight,reduced glycosylated hemoglobin,and low incidence of adverse reactions.Recent research has indicated that glucagon-like peptide-1 receptor agonists play a great role in cardiovascular protection through anti-oxidant stress,inhibiting inflammation,improving insulin sensitivity and other pathological processes.This article reviewed all the aspects above in research on mechanism of cardiovascular protection of glucagon-like peptide-1 receptor agonists.

关 键 词：胰高血糖素样肽-1受体激动剂 心血管保护 2型糖尿病 

分 类 号：R972[医药卫生—药品]